Navigation Links
Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results
Date:9/14/2009

CHERRY HILL, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX) announces today that results from the Company's ongoing sponsored research studies indicate that Oraphyte(TM) can control nematode infestation pre-plant and post-plant in several species of turfgrass. In the coming months Nuvilex intends to initiate trials on golf course greens in the Southeastern United States under conditions that are most optimal for turfgrass growth. These commercial studies will determine and validate Oraphyte's usage requirements and application specifications. Nuvilex plans to register Oraphyte with the Environmental Protection Agency (EPA) in two phases: Nuvilex will first register Oraphyte(TM) with the EPA as a pesticide for use on terrestrial, non-food crops, followed by pesticide registration for use on high-value crops (e.g., terrestrial food crop use) such as soybeans and sugar cane.

From 2007 to 2009, renowned nematologist Edward McGawley, Ph.D. of the Louisiana State University Agricultural Center (LSU AgCenter) has investigated the use of Oraphyte(TM) as an all-natural nematocide for turfgrass. Initial greenhouse and Phase 1 microplot experiments conducted in 2007 and 2008 demonstrated that Oraphyte(TM) could control populations of nematodes in turfgrass; however, early formulations appeared to be phytotoxic.

From May to August 2009, Phase 2 microplot experiments conducted at the LSU AgCenter included the application of a new and improved Oraphyte(TM) formula to six nematode genera that were added to the soil of Agrostis stolonifera (Penn G2 Bentgrass) and Cynodon (Bermudagrass). Both species of turfgrass were grown in microplots in a controlled environment. Each microplot contained approximately 15-35 kg of soil and approximately 1.7 ft2 of turfgrass. Preliminary results showed that the new and improved formulations caused a statistically significant reduction in the number of nematodes that remained in the soil upon the completion of the experiment. In addition, Oraphyte(TM), as determined by measuring the mean cumulative turfgrass clipping weights, does not appear to be phytotoxic to turfgrass. The cumulative grass clipping weights of microplots that received Oraphyte(TM) were not statistically different from the controls that received no pesticide and no nematodes. The final report on the LSU Phase 2 microplot trials will be issued on or before October 31, 2009.

"The transition from laboratory to commercial testing for Oraphyte(TM) is a very important step in the product's evolution to market launch," stated Martin Schmieg, Chairman and Chief Executive Officer of Nuvilex, Inc. "The demand for an all-natural, eco-friendly nematocide amongst golf course superintendents and farmers continues to increase as the number of EPA-registered synthetic nematocides decreases. We anticipate, with continuing positive test results, that the market acceptance of Oraphyte(TM) as a major product in the new eco-friendly pesticide market will be strong."

About Oraphyte(TM)

Oraphyte(TM) is an all-natural, eco-friendly, biodegradable nematocide for turfgrass and high-value crops. Oraphyte(TM) can be formulated as a liquid or solid and is composed of orange terpene oil, Valencia orange oil, hydrogen peroxide, sorbitan monooleate, and distilled water. All of Oraphyte's ingredients are listed on the Office of Prevention, Pesticides, and Toxic Substances (OPPTS) of the United States Environmental Protection Agency's (EPA) inert ingredient list.

From 2007 to 2009, Oraphyte has undergone testing at Louisiana State University, Auburn University, the University of Florida, Ohio State University, and the USDA to determine its efficacy and usefulness as a non-toxic, low-cost alternative to many traditional nematocides, including Nemacur, Curfew, Telone II, and Temik.

About Nuvilex, Inc.

Nuvilex, Inc. is an emerging healthcare consumer products company. The Company's lead products include: Last Shot Hangover Remedy(TM), a unique sugar-free, calorie-free and caffeine-free liquid formula designed to ease the symptoms of a hangover; Cinnergen(TM), which promotes a healthy glucose metabolism; Cinnechol(TM), designed to help maintain normal cholesterol levels and support normal cardiovascular function; and Infinitink( (R)), a permanent yet more easily removable tattoo ink. The Company's complete portfolio spans aesthetics, dermatology, environmental and nutraceutical products, all of which are designed to directly or indirectly improve human health. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., the developer of Infinitink( (R)). In conjunction with the merger, the Company changed its name to Nuvilex, Inc. from eFoodSafety.com. Please visit www.nuvilex.com for additional information on the Company.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., the Company's ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Company Contact:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula
2. Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
3. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
4. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
5. Nuvilex, Inc. Announces Business Update Conference Call
6. Nuvilex, Inc. Announces Monthly Investor Conference Call
7. Nuvilex, Inc. Announces Investor Conference Call and Open House
8. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
9. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
10. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
11. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, ... members and suppliers for its inaugural Member Conference at the Paris Hotel in ... elevating the operational health of America’s healthcare providers. , The conference was highlighted ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found ... The 550 employees of Sun Health Senior Living (SHSL) may not share ... their doctor and prescription copays for the year, while holding the line on increasing ...
(Date:5/26/2016)... ... , ... The Lung Institute has partnered with the Gulfcoast North ... 6 at their clinic in downtown Tampa. The class is complimentary for the public. ... created a free downloadable 4 Week Smoking Cessation Guide for those who ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eugene Batelli, ... Along with his wonderful accolades and stellar patient reviews, Dr. Batelli continues to ... , Dr. Eugene Batelli is a highly trained Podiatric Surgeon who specializes in ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)... May 24, 2016 Cirujanos holandeses ... ayudar a los médicos a compartir sus mejores prácticas ... escala mundial. Profesionales médicos de Europa, África, ... apuntado a la aplicación, que combina la transmisión en ... totalmente seguro. Educación   "Imagine un ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology: